Search

We present a rigorous theoretical basis of the kinetic method, commonly used for thermochemical determinations in mass spectrometry, based on finite heat bath theory (FHBT) developed by Klots. A simple analytical expression for the branching ratio is derived from FHBT formalism. This expression simplifies to the expression given by the absolute reaction rate theory (1) for very large clusters or (2) for reactions having a negligible kinetic shift. The reacting population is described by two different temperatures rather than by the “effective” temperature as suggested previously. Simulations performed using both RRKM and FHBT revealed that the kinetic plots are slightly nonlinear. The observed curvature is related to the changes in the transition state temperature as a function of the critical energy for fragmentation. The curvature of the plots decreases for larger clusters. We show that the “effective” temperature closely resembles the average value of the transition state temperature. This allows us to assign a new definition of the effective temperature and predict its properties. The results of simulations confirm that the extended version of the kinetic method introduced by Fenselau and co-workers provides accurate relative energetics for competitive reactions for both small and large ions. However, accurate thermochemical information can be obtained from the kinetic method only if reactions under investigation have negligible reverse activation energies. A new approach for extracting relative fragmentation energetics and entropy differences for two competing reactions is proposed. This approach requires a measurement of kinetic energy release distributions (KERDs) for the two fragmentation channels; the relative energetics and dynamics can be extracted from a single measurement.

The collision energy dependence of the fragmentation of the 1-bromonaphthalene radical cation was studied using sustained off-resonance excitation (SORI) in a 7 T Fourier transform ion cyclotron resonance mass spectrometer (FTMS). Fragmentation efficiency curves were obtained as a function of collision energy at four different pressures of Ar bath gas corresponding to collision numbers of 3, 5, 15, and 20. The results were modeled using RRKM/QET formalism. A refined analytical form for the collisional energy deposition function is proposed. The ability to obtain accurate fragmentation energetics of a complex system using the present approach is demonstrated. The “effective temperatures” deduced from the average internal energies for C6H5Br^+• and C10H7Br^+• were found to be the same for both ions provided the bath gas pressure and the maximum value of center-of-mass collision energy were the same. The range of effective temperatures from 1000 to 3700 K sampled in the present study significantly exceeds the temperature range accessible by blackbody infrared radiative dissociation (BIRD). We anticipate that the present approach can be used to study fragmentation energetics of biomolecules.

Using a high performance electron gun, electron-induced ionization and excitation of fullerene ion beams is achieved in the second field-free region of a reversed-geometry double-focusing mass spectrometer. Excitation of mass-selected C60z+ion beams leads to consecutive C2eliminations, which are observed in mass-analyzed ion kinetic energy (MIKE) spectra. Electron-induced decay of the ions takes place on a short time scale of 0–3 μs. Average kinetic energy release (KER) values were determined for the electron-induced C2eliminations from C60z+ions with z= 2–4 and were invariably found to be higher than for the corresponding spontaneous eliminations. The results are interpreted as being due to a time-dependent KER, since the non-fixed energy in the transition state is increased for higher internal energies and shorter lifetimes of the reactant ions. These results are compared with time-resolved KER values obtained previously, using an ion trap/reflectron instrument, for C2elimination from C60+. The two sets of data are modeled by finite heat bath theory (FHBT) using calculated rate energy dependencies. Calculations are performed using currently available information on the activation parameters. The dissociation is modeled with an Arrhenius pre-exponential factor, A= 5 × 1019s−1(at a temperature KBT= 0.2 eV) and a vaporization (activation) energy ΔEvap= 10.3 eV. Modeling the data necessitates inclusion of radiative decay in parallel with the dissociation. Radiative decay is dominant at times longer than a few microseconds.

Psoralens in combination with ultraviolet light (UVA; 320-400 nm) are used in the photochemical treatment of a variety of skin diseases including vitiligo, a skin depigmentational disorder, and psoriasis, a disease of accelerated epidermal cell proliferation. Although it is generally assumed that the major site of action of the psoralens is DNA, we have obtained evidence that another site may be the primary target for these compounds. We have identified specific, saturable, high-affinity binding sites for 8-methoxypsoralen on HeLa cells and have detected specific binding of 8-methoxypsoralen to four other human cell lines and five mouse cell lines. In HeLa cells, specific binding is reversible and independent of the ability of the compound to intercalate into DNA. In addition, binding sites become covalently modified by the psoralen after UVA exposure. Specific binding of 8-[methoxy-3H]methoxypsoralen constitutes 79% of the label bound to the cells. Scatchard analysis indicated two classes of psoralen binding sites: high-affinity sites with a Kd of 19 X 10(-9) M (1.8 X 10(5) sites per cell) and low-affinity sites with a Kd of 4 X 10(-6) M (7.1 X 10(6) sites per cell). Four structurally related psoralen analogs block 8-methoxypsoralen binding in a manner that parallels their biological activity. Based on these findings, we hypothesize that specific binding sites for psoralens on mammalian cells mediate, at least in part, psoralen-induced phototoxicity.

We found that two markers of differentiation, tyrosinase (monophenol, dihydroxyphenylalanine:oxygen oxidoreductase, EC 1.14.18.1) activity and melanin synthesis, are induced by diazepam in B16/C3 mouse melanoma cells. We also demonstrated high-affinity binding sites for [3H]diazepam in these cells by radioreceptor assay, and we visualized binding to the cell surface by fluorescence microscopy with a benzodiazepine analog conjugated to a fluorescein-labeled protein. Our studies also showed that there are differences between the binding characteristics in intact cells and in membrane fractions prepared from these cells. Scatchard analysis of the binding data from membrane fractions gave a linear plot (Kd = 9.1 X 10(-8) M). With intact cells, a curvilinear Scatchard plot was obtained. This was resolved into two components defining binding sites with affinity constants of 1.7 X 10(-9) M and 4.6 X 10(-7) M. Thus, it appears that [3H]diazepam binding in intact cells is more complex than in isolated membranes. Several related benzodiazepines, including flunitrazepam, Ro-5-4864, nitrazepam, oxazepam, lorazepam, Ro-5-3072, chlordiazepoxide, and clonazepam also induced melanogenesis. When these compounds were tested for their ability to inhibit [3H]diazepam binding, flunitrazepam, diazepam, and Ro-5-4864 were found to be the most effective inhibitors. These three compounds were also the most potent in inducing melanogenesis. Our results suggest that the benzodiazepines modulate cell differentiation. The presence of high-affinity binding sites in this homogeneous, easily grown cell line may provide a useful model for studies on the mechanism of action of these compounds.

One of the more prominent clinical treatments for skin diseases such as psoriasis and vitiligo involves the use of a combination of psoralens and UV light, a procedure referred to as PUVA chemotherapy. This drug regimen markedly alters epidermal cell growth and differentiation. In many cell types, an early cellular event following treatment of cells with PUVA is inhibition of binding of epidermal growth factor (EGF) to its receptor. To examine the mechanism underlying this effect, we used A431 cells, a human epidermal cell line known to express large numbers of EGF receptors. We found that exposure of A431 cells to PUVA caused a dramatic inhibition of EGF-stimulated EGF receptor tyrosine kinase activity. Inhibition required intact cells and did not appear to be mediated by protein kinase C, because this inhibition was apparent in cells in which the enzyme was down-regulated by phorbol ester pretreatment and in cells treated with inhibitors of protein kinase C. Inhibition of tyrosine kinase activity by PUVA was distinct from other inhibitors of EGF receptor function in that it was associated with a rapid increase in the amount of phosphate incorporated into serine residues of the EGF receptor. This suggested that PUVA-induced serine phosphorylation may mediate EGF receptor kinase activity. These results demonstrate that alterations in EGF receptor function may contribute to the therapeutic efficacy of PUVA in photo-chemotherapy.

The psoralens, when activated by ultraviolet light of 320-400 nm (UVA light), are potent modulators of epidermal cell growth and differentiation. Previously, we reported that, in mammalian cells, these compounds bind to specific saturable high-affinity cellular receptor sites. In the present studies, we demonstrate that binding of psoralens to their receptors followed by UVA light activation is associated with inhibition of epidermal growth factor (EGF) receptor binding. Inhibition of EGF binding, which required UVA light, was rapid and dependent on the dose of UVA light (0.5-2.0 J/cm2), as well as the concentration of psoralens (10 nM to 1 microM). Higher doses of UVA light (2.0-6.0 J/cm2) by themselves were also inhibitory, indicating that psoralens potentiate the UVA-induced inhibition of EGF binding. A number of biologically active analogs of psoralen, including 8-methoxypsoralen, 5-methoxypsoralen, and 4,5',8-trimethylpsoralen, when activated by UVA light, were found to be inhibitors of binding. Inhibition of EGF binding by psoralens was observed in a variety of human and mouse cell culture lines known to possess psoralen receptors. In the epidermal-derived line PAM 212, at least two populations of receptors with different affinities for EGF were found. Psoralens and UVA light selectively inhibited binding to the higher-affinity EGF receptors, an effect analogous to that of the phorbol ester tumor promoters. As observed with phorbol esters, photoactivated psoralens appeared to inhibit EGF binding by an indirect mechanism. These data demonstrate that the psoralens and UVA light have direct biological effects on cell-surface membranes. Since EGF is a growth-regulatory peptide, the ability of psoralens and UVA light to inhibit EGF binding may underlie the biologic effects of these agents in the skin.

Psoralens in combination with ultraviolet light are potent modulators of epidermal cell growth and differentiation. Responsive cell types contain specific, saturable, high-affinity binding sites for the psoralens. These binding sites become covalently modified by the psoralen molecule following ultraviolet light exposure. In the present studies the psoralen receptor, labeled with [3H]8-methoxypsoralen, was visualized in the cytoplasmic and plasma membrane fractions of HeLa cells following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The receptor had an apparent molecular mass of approximately 22,000 daltons and was shown to be sensitive to protease, but not nuclease treatment. The radiolabeled receptor could not be visualized in nuclear extracts of cells. Covalent binding of the radioligand to the receptor protein was inhibited by excess unlabeled 8-methoxypsoralen, indicating that covalent psoralen-receptor binding was saturable. In addition, the covalently modified receptor was found to persist in cells for over 5 h. The presence of a cellular protein that exhibits specific affinity for the psoralens and becomes photoalkylated by these compounds, together with previous data showing that the psoralens have direct effects on the cell surface membranes, supports our model that some of the biological effects of photoactivated psoralens are receptor-mediated.

The B16/C3 murine melanoma is a pigmented tumor that is rich in the copper-containing enzyme, tyrosinase. This enzyme, which converts tyrosine to melanin precursors, is largely associated with membrane fractions of cells and exists in a number of discrete isozymic forms ranging in molecular mass from 58,000 to 150,000 daltons and pI from 3.4 to 5.2. One of these isozymes (Mr = 58,000, pI 3.4) has been purified to homogeneity. The purified enzyme catalyzes the hydroxylation of L-tyrosine to L-dihydroxyphenylalanine (L-DOPA) and the conversion of L-DOPA to dopaquinone. Ascorbic acid, tetrahydrofolate, and dopamine can serve as cofactors in the hydroxylase reaction. The Michaelis constants for the purified enzyme were 7 X 10(-4) M for L-tyrosine and 6 X 10(-4) M for L-DOPA. The Vmax for L-DOPA was much greater than the Vmax for L-tyrosine indicating that tyrosine hydroxylation is rate-limiting in melanin precursor biosynthesis. Two putative copper chelators, phenylthiourea and diethyldithiocarbamide inhibited both the tyrosine hydroxylase and L-DOPA oxidase activities of the enzyme. Phenylthiourea was a noncompetitive inhibitor while diethyldithiocarbamide was a competitive inhibitor indicating that these agents act by different mechanisms. When digested with proteases and glycosidases, higher molecular weight forms of tyrosinase co-migrated with the purified enzyme in isoelectric focusing and sodium dodecyl sulfate-polyacrylamide gel electrophoresis suggesting that the isozyme was derived from larger precursors. Thus, post-translational processing of tyrosinase may underlie isozyme diversity and this may be important in the control of melanogenesis in this tumor model.

Topical application of beta-naphthoflavone to CD-1 mice induced an 87-fold increase in epidermal 7-ethoxyresorufin O-dealkylation activity per cell and a many-fold increase in epidermal cytochrome P-4501A1 (CYP1A1) concentration. Flow cytometric analysis of individual epidermal cells from acetone-treated and beta-naphthoflavone-treated mice using a monoclonal antibody for CYP1A1 indicated that 50% to 60% of the isolated epidermal cells were refractory to beta-naphthoflavone induction of CYP1A1. Examination of the differences between responsive and nonresponsive epidermal cells from beta-naphthoflavone-treated mice revealed that 70% of the low CYP1A1-containing cells (noninduced) separated by flow cytometry were basal cells and only 12% were suprabasal differentiated cells. In contrast, about 50% of the high CYP1A1-containing induced cells separated by flow cytometry from the epidermis of mice treated with beta-naphthoflavone were suprabasal cells and 35% were basal cells. These results indicate that topical application of beta-naphthoflavone increased the level of CYP1A1 in about 80% of the separated suprabasal cells and in about 35% of the separated basal cells.

We describe the case of an 11-month-old girl with a rare cerebellar glioblastoma driven by a NACC2-NTRK2(Nucleus Accumbens Associated Protein 2-Neurotrophic Receptor Tyrosine Kinase 2) fusion. Initial workup of our case demonstrated homozygous CDKN2Adeletion, but immunohistochemistry for other driver mutations, including IDH1 R132H, BRAF V600E, and H3F3A K27M were negative, and ATRX was retained. Tissue was subsequently submitted for personalized oncogenomic analysis, including whole genome and whole transcriptome sequencing, which demonstrated an activating NTRK2fusion, as well as high PD-L1 expression, which was subsequently confirmed by immunohistochemistry. Furthermore, H3and IDHdemonstrated wildtype status. These findings suggested the possibility of treatment with either NTRK- or immune checkpoint- inhibitors through active clinical trials. Ultimately, the family pursued standard treatment that involved Head Start III chemotherapy and proton radiotherapy. Notably, at most recent follow upapproximately two years from initial diagnosis, the patient is in disease remission and thriving, suggesting favorable biology despite histologic malignancy. This case illustrates the value of personalized oncogenomics, as the molecular profiling revealed two actionable changes that would not have been apparent through routine diagnostics. NTRKfusions are known oncogenic drivers in a range of cancer types, but this is the first report of a NACC2-NTRK2fusion in a glioblastoma.LEARNING OBJECTIVESThis presentation will enable the learner to:1.Explore the current molecular landscape of pediatric high grade gliomas2.Recognize the value of personalized oncogenomic analysis, particularly in rare and/or aggressive tumors3.Discuss the current status of NTRK inhibitor clinical trials